Hoffman-LaRoche’s Accutane (isotretinoin) — approved by the U.S. Food and Drug Administration (FDA) in 1982 — is an acne medication. American researchers first studied isotretinoin in 1975. Originally a chemotherapy drug, Accutane became a blockbuster acne medication. It quickly proved to be a miracle for some, offering blemish-free skin to those who had given up after trying many other treatments.
At the height of sales, Accutane made $700 million a year for Roche. According to the FDA, about 5 million Americans took the drug from 1982 to 2000.
The drug works for severe (cystic) acne, providing long-lasting and sometimes complete reduction of acne for 85 percent of patients, according to the American Academy of Dermatology.
However, the drug also has serious side effects like Crohn’s disease. It also has been linked to severe birth defects. For this reason, the FDA ordered a black-box warning — the most serious warning — indicating women who are pregnant or who may become pregnant should not take Accutane.
Following numerous reports of adverse events and injury lawsuits, Roche stopped manufacturing Accutane in 2009. Generic brands of the medication — including Amnesteem, Claravis and Sotret — are still available.
How Accutane Treatment Works
Accutane is part of a class of medications called retinoids — drugs used to treat cancer. Accutane is especially effective at treating acne that has not responded to antibiotics.
The medication is a derivative of vitamin A and works by controlling the secretion of sebum – an oily substance – in the sebaceous glands. The acne it treats consists of nodules with a diameter or 5 mm or greater. Having this type of acne can be socially debilitating, so the potential of a cure can be life changing. Undergoing Accutane treatment is a commitment of time and energy. It can take months to be effective, and patients often must deal with side effects like dry eyes and headaches.
In addition, acne may worsen during the beginning stages of treatment before it starts to clear up.
Accutane Side Effects
Accutane is extremely effective at treating acne, but it also comes with a number of common and serious side effects. These adverse events range from fatigue to serious psychiatric disorders. One of the most dangerous side effects is severe birth defects. Some of the common Accutane side effects may subside after initial treatment, but patients who continue to suffer side effects should contact their doctor.
In clinical trials and postmarketing experience, participants suffered a number of serious Accutane side effects. According to the medication insert, some side effects and adverse reactions are similar to those in patients taking high doses of vitamin A.
|Dry skin, itching or rash||Nosebleeds||Dry mouth and lips|
|Cracked or peeling skin||Dry eyes||Dizziness|
|Muscle, back and joint pain||Inflammation in the eyes|
|Drowsiness||Fatigue||Fingernail and toenail changes|
|Headache||Cold symptoms||Unusual hair growth|
|Slow-healing cuts or sores||Bleeding or swollen gums|
|Serious Side Effects|
|Allergic reactions||Psychiatric disorders (depression, suicidal thoughts and aggressive and violent behavior)||Pseudotumor cerebri (pressure buildup in the skull that mimics a brain tumor)|
|Pancreatitis (inflammation of the pancreas)||Elevated cholesterol||Hearing impairment|
|Hepatitis||Inflammatory bowel disease||Decreased night vision|
FDA Black Box Warning for Birth Defects
In 1985, the FDA added a black box warning to Accutane for an extremely high risk of severe birth defects. Birth defects and fetal deaths can occur if pregnant patients take Accutane — even for a short amount of time.
Birth defects include:
- Abnormalities of the ear
- Abnormalities of the eye
- Facial dysmorphia
- Cleft palate
- Brain problems
- Heart problems
Accutane and Pregnancy
The FDA gave Accutane a pregnancy rating of X. This means women should not take it during pregnancy because there is evidence of fetal abnormalities.
The FDA reported that infants whose mothers took Accutane were born with both internal and external abnormalities such as cleft palate, missing ears, facial dysmorphism and central nervous system malformations. In fact, among Accutane-exposed pregnancies, 42 percent of infants suffer from birth defects.
Because of the high risk of miscarriage and deformities, the FDA worked with Roche to create programs to ensure that Accutane users were not and would not become pregnant.
By 1988, the U.S. started a pregnancy prevention program with the goal of decreasing the number of woman getting pregnant while taking the drug. The program was eventually effective in decreasing the percentage of woman getting pregnant while taking the drug, from 4 women per every 1,000 a year to less than 2 for every 1,000. However the number of prescriptions given out also increased, keeping the number of affected pregnant women taking Accutane high.
Other countries had even stricter rules about Accutane use by women of childbearing age. For example, in Britain, prior to receiving the medication, women were required to agree to have an abortion if they became pregnant during treatment.
The first formal U.S. program called System to Manage Accutane Related Teratogenicity (SMART) arrived in 2002.
Under the program, physicians placed qualification stickers on prescriptions to inform the pharmacist that the patient meets the requirements and can take Accutane. The enrolled patients signed consent forms and watched educational videos and read information guides. In addition, doctors and pharmacists were required to read literature on the risks.
In 2006, a stricter system called the iPLEDGE program replaced SMART. The computer-based system required registration by pharmacies, doctors and patients. Patients had to get negative pregnancy tests from approved labs before receiving the medication. Prescriptions only covered 30 days at a time, and users were required to utilize two types of birth control.
According to a study funded by the Canadian Institutes of Health Research and published in 2007 in the British Journal of Clinical Pharmacology, the rate of elective abortions for patients who got pregnant during Accutane use was 84 percent. This rate was based on 90 women out of 8,609 who became pregnant while taking Accutane. Of the remaining pregnant women, three had spontaneous abortions, two had delivery trauma that resulted in neonatal death and nine infants survived. One of the nine was born with face and neck abnormalities.
Accutane FDA and Doctor Warnings
The first prescriptions of Accutane were written in 1982, and a few months later came the first report of a baby born with malformations after Accutane was taken during pregnancy. In 1983, there were two “Dear Doctor letters” — special communications the FDA requires drug manufacturers to send if the drug label is not complete in covering the extent and severity of side effects — issued, alerting physicians of the possibility of birth defects. From 1984 to 1988, seven more of the letters went out.
The FDA was not alone in noting the dangers of Accutane. Dr. Frank Yoder, one of the scientists involved in the discovery of Accutane, wrote a letter to the Journal of the American Medical Association in 1983, informing the public of the possibility that Roche was not clear in alerting users of the toxicity associated with Accutane.
That same year, a nonprofit health advocacy group, Public Citizen, petitioned the FDA to add warnings of birth defects to Accutane labels. The FDA took action in 1985 and added a black-box warning to the label indicating that Accutane can cause fetal deformities and possibly fetal death.
The Centers for Disease Control and Prevention played a role in affirming the danger of Accutane by publishing information on the fetal toxicity of the drug, conducting a study of Accutane-exposed pregnancies to raise awareness.
Also, the CDC’s Division of Birth Defects and Developmental Disabilities received reports of infant death following maternal exposure to Accutane.
Accutane Market Withdrawal
In June 2009, as the number of adverse events reported to the FDA and lawsuits from patients continued to grow, Roche stopped manufacturing the Accutane brand-name drug. But the company said it was an economic decision based on generic brands of the medication taking over the market. Accutane was recalled in other countries.
Not only does Accutane come with a variety of side effects, it also has a lengthy list of drug interactions. Some are more serious than others. The medication label lists the most important interactions.
- Vitamin A: Taking vitamin A with Accutane can cause toxicity.
- Tetracyclines: Using Accutane with these drugs can increase the risk of pseudotumor cerebri (benign intracranial hypertension), a condition where pressure builds up in the skull.
- Micro-dosed progesterone preparations: These types of birth control may be inadequate when taking Accutane.
- Norethindrone/ethinyl estradiol: Accutane may decrease the effectiveness of this type of birth control.
- St. John’s Wort: Taking St. John’s Wort for Accutane-related depression with birth control may reduce the effectiveness of the birth control and lead to pregnancy while on Accutane.
- Phenytoin: Because Accutane may cause bone loss and phenytoin may lead to low bone mineral density, doctors should monitor patients who take these drugs together.
- Systemic Corticosteroids: Studies link systemic corticosteroids to osteoporosis. There are no clinical trials that suggest an increase of bone loss when Accutane is taken with these drugs. Doctors should exercise caution in prescribing these together.
While brand name Accutane is no longer available, several generics still exist and use the same dosage chart. Recommended doses of isotretinoin range from 0.5 to 1.0 mg/kg body weight per day. It comes in capsules of 10, 20 and 40 mg, and patients should take it with food. Most patients take the medication for 15 to 20 weeks and may repeat the treatment course if acne returns.
Due to the risk of serious birth defects, women of childbearing age must commit to programs aimed at preventing pregnancies during treatment.
Please seek the advice of a medical professional before making health care decisions.
Michelle Y. Llamas is a senior content writer. She is also the host of Drugwatch Podcast where she interviews medical experts as well as patients affected by drugs and medical devices. She has written medical and legal content for several years — including an article in The Journal of Palliative Medicine and an academic book review for Nova Science Publishers. With Drugwatch, she has developed relationships with legal and medical professionals as well as with several patients and support groups. Prior to writing for Drugwatch, she spent several years as a legal assistant for a personal injury law firm in Orlando. She obtained her English – Technical Communication degree from the University of Central Florida. She is a committee member with the American Medical Writers Association.